CNC vs RPRX: Which Stock Is the Better Buy?
Centene Corporation and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CNC vs RPRX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Centene Corporation (CNC) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $30.7B | $31.6B |
| Revenue (latest FY) | $194.78B | $2.38B |
| Net income (latest FY) | $-6.67B | $770.95M |
| Revenue growth (5y CAGR) | 11.9% | 2.3% |
| Net margin | -3.4% | 32.4% |
| Return on equity | -33.4% | 11.9% |
| P/E ratio | — | 28.9 |
| Dividend yield | — | 1.7% |
| Profitable years (of last 10) | 9 | 8 |
| Positive free cash flow | Yes | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CNC vs RPRX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CNC's full financials → Open RPRX's full financials →More comparisons
Frequently asked questions
Which is bigger, CNC or RPRX?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $30.7B.
Which grows faster, CNC or RPRX?
Over the last five fiscal years, Centene Corporation grew revenue faster — 11.9%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CNC fundamentals → · RPRX fundamentals → · All 1,500+ companies → · Free screener →